The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

(2021) Matthew McCallum et al.   CELL

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

(2021) Markus Hoffmann et al.   CELL

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

(2021) Georg MN Behrens et al.   LANCET

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) Joana Barros-Martins et al.   NATURE MEDICINE

SARS-CoV-2 variants, spike mutations and immune escape

(2021) William T. Harvey et al.   NATURE REVIEWS MICROBIOLOGY

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

(2020) Fabian Schmidt et al.   JOURNAL OF EXPERIMENTAL MEDICINE